← Leaderboards
Peter J Allen
Van Andel Research Institute
$7,723,827
Attributed
$14,019,636
Total exposure
6
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$14,019,636 · 6
By mechanism
R01$6,117,146 · 2
U01$5,755,329 · 1
T32$1,712,563 · 2
R21$434,598 · 1
Top collaborators
- Randall Brand12 shared
- Brian B Haab12 shared
- Carlos Fernandez-Del Castillo5 shared
- David H Harpole5 shared
- Christopher L. Wolfgang5 shared
- Eun-Sil Shelley Hwang3 shared
- Herbert Kim Lyerly3 shared
Others in their field
Top investigators on “Malignant Neoplasm Of Pancreas”
- David Heimbrook · Leidos Biomedical Research, Inc.$73,277,592
- Anirban Maitra · Johns Hopkins University$43,028,398
- Walter John Curran · Thomas Jefferson University$26,641,549
- Surinder Kumar Batra · University Of Pittsburgh At Pittsburgh$26,074,679
- Michael A Hollingsworth · University Of Nebraska Medical Center$23,837,917
- Robert E Reiter · University Of California Los Angeles$21,473,394
Research focus
Malignant Neoplasm Of PancreasExcisionPancreasLaboratoriesSamplingCyst FluidTechnologyValidationMalignant - DescriptorMalignant NeoplasmsDouble-Blind MethodMolecularAntibodiesBiological MarkersDiagnosisEarly DiagnosisCystic NeoplasmDiagnosticPapillaryMucinous NeoplasmPancreatic CystPerformanceHigh RiskLesion
Grant awards (32)
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$406,824
R01 · FY2025 · CA · contact PI
Duke Research Training Program in Surgical Oncology$373,556
T32 · FY2025 · CA
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$386,483
R01 · FY2024 · CA · contact PI
Duke Research Training Program in Surgical Oncology$181,243
T32 · FY2024 · CA
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)$541,606
R01 · FY2023 · CA · contact PI
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$422,074
R01 · FY2023 · CA · contact PI
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)$602,528
R01 · FY2022 · CA · contact PI
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)$614,787
R01 · FY2021 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$374,611
U01 · FY2021 · CA
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)$620,701
R01 · FY2020 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$548,627
U01 · FY2020 · CA
Translational Research in Surgical Oncology$338,434
T32 · FY2020 · CA
Preventing an Incurable Disease: The Prevention of Progression to Pancreatic Cancer Trial (The 3P-C Trial)$552,342
R01 · FY2019 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$521,859
U01 · FY2019 · CA
Translational Research in Surgical Oncology$373,223
T32 · FY2019 · CA
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$553,441
U01 · FY2018 · CA
Translational Research in Surgical Oncology$446,107
T32 · FY2018 · CA
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$339,622
R01 · FY2018 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$554,248
U01 · FY2017 · CA
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$349,513
R01 · FY2017 · CA · contact PI
Detection and prognosis of early-stage pancreatic cancer by interdependent plasma markers$623,533
U01 · FY2016 · CA
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$349,513
R01 · FY2016 · CA · contact PI
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$437,758
R01 · FY2015 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$101,267
U01 · FY2015 · CA
Biomarker validation for intraductal papillary mucinous neoplasms of the pancreas$493,395
R01 · FY2014 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$389,914
U01 · FY2014 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$530,069
U01 · FY2013 · CA
Antibody bead array technology for diagnosis of pre-invasive pancreatic cancer$238,685
R21 · FY2012 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$224,231
U01 · FY2012 · CA
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$601,107
U01 · FY2011 · CA
Antibody bead array technology for diagnosis of pre-invasive pancreatic cancer$195,913
R21 · FY2011 · CA · contact PI
Detection of Pre-Invasive Pancreatic Cysts Using Protein and Glycan Biomarkers$732,422
U01 · FY2010 · CA